Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Cancer
- Genome
- Test/Monitoring
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 299285
IPSCIO Record ID: 299283
Licensor also grants to the right to issue sublicenses.
Licensee has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene.
Licensed technology also includes
— the human BRCA2 gene(s);
— any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s);
— any BRCA2 protein molecules;
— nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence;
— any mutations or altered form of the BRCA2 gene(s);
— any animal or human homologues of the BRCA2 gene(s);
— any other 'technologies' and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.
Licensed technology further includes all uses of the BRCA2 gene(s) and its products, should they be isolated, characterized, developed or sequenced under this research collaboration, including such uses as diagnostic and therapeutic applications.
IPSCIO Record ID: 299284
The Licensor also grants an exclusive license to practice non-patentable proprietary licensed technology in making, having made, using or selling licensed products and to practice the licensed methods throughout the world where Licensor may lawfully grant such a license.
And, Licensor grants the right to issue sublicenses.
Licensee has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene.
Licensed technology also includes
— the human BRCA2 gene(s);
— any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s);
— any BRCA2 protein molecules;
— nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence;
— any mutations or altered form of the BRCA2 gene(s);
— any animal or human homologues of the BRCA2 gene(s);
— any other 'technologies' and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.
